Saturday, June 25, 2022

US Stem Cell Inc (OTCMKTS:USRM) is Back on Our Radar

US Stem Cell Inc (OTCMKTS:USRM) has been gaining back some of its loss from last month. It might be that the markets are starting to focus on the science of USRM and not the less than healthy financials.
USRM bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. USRM’s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
US Stem Cell Inc (OTCMKTS:USRM) is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases.
According to company materials, “US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function.
You can find out when $USRM stock reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

Market are yet to react to the company’s most recent news, which symboilizes a major step forward for US Stem Cell in terms of validation of its lead technology and the primary application of this technology to the healthcare space.
Specifically, the news details the publication of a preclinical trial of US Stem Cell’s osteoarthritis treatment. The science that underpins this treatment is pretty much the same across the whole spectrum of different target indications and that’s why this validation is so important.
Essentially, the company removes fat cells from the patient through liposuction and then extracts stem cells from this removed fat. It then injects the stem cells (directly) into the region of the body for which the patient requires treatment.
USRM just recently released results from a study where stem cell treatment was injected into patient’s knees and patients were asked to walk for 6 minutes after the WOMAC test. The treatment numbers proved to be successful.
Across the ten patients, average WOMAC reduced to 52 at 3 months, 46 at 6 months, 42 at 1 year, 38 at 1.5 years, and 41 at 2 years. This is after one round of treatment. All of these reductions were statistically significant, recorded at p-values of 0.01 or less. Similarly, the treatment resulted in an improvement in the 6MWD test at 3 and 6 months and 1, 1.5, and 2 years post treatment.
The study is not enough to validate the treatment in total, but if the upcoming tests continue to validate this treatment, the stock could take a run.
US Stem Cell Inc (OTCMKTS:USRM) has great science and cash to burn for the moment – after a $5 million financing – but investors need watch out for dilution. USRM is carrying a $17.56 million market cap and 335.43 million shares outstanding. We will be watching news on this company and if the therapy results are promising again, the market may not ignore it for a second time. However, as all investors know, biotech is a risky endeavor, regardless. For continuing coverage on shares of $USRM stock, as well as other breakout stock picks, sign up for our free newsletter today and get our next hot stock pick!

Related Articles


Please enter your comment!
Please enter your name here

Stay Connected


Latest Articles